Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

73
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.5K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-dimensional culture models of hepatitis B virus infection: Progress, challenges, and opportunities.

Virology·2026
Same author

Draft genome of extended-spectrum β-lactamase-producing multidrug-resistant <i>Salmonella enterica</i> serovar Brandearup strain DE0603 from an urban river in South Africa.

Microbiology resource announcements·2026
Same author

Structural mimics of SARS-CoV-2.

Infection·2026
Same author

A river in crisis: water quality, microbial burden, and public health implications of a South African urban river.

Applied and environmental microbiology·2025
Same author

Molecular Characterisation of Escherichia coli Collected From an Urban River in Johannesburg, South Africa.

Environmental microbiology reports·2025
Same author

Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice.

Viruses·2025
Same journal

Applications of lupeol to manage fungal infections: a promising multi-target molecule.

Future microbiology·2026
Same journal

Benzyl isothiocyanate-loaded chitosan beads: a novel strategy to combat biofilm formation by <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>.

Future microbiology·2026
Same journal

<i>Mycobacterium colombiense</i> isolation among people living with human immunodeficiency virus: a case series.

Future microbiology·2026
Same journal

Thwarting the biothreat in the 21st century: means and methods.

Future microbiology·2026
Same journal

The oral-respiratory interface: modulation of <i>Streptococcus pneumoniae</i> serotype adhesion by the periodontal pathogen <i>Porphyromonas gingivalis</i> W83.

Future microbiology·2026
Same journal

Global One Health genomics identify conserved virulence and mobile resistance in the opportunistic pathogen <i>Staphylococcus saprophyticus</i>.

Future microbiology·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K

Recent advances in developing nucleic acid-based HBV therapy.

Musa Marimani1, Justin Hean, Kristie Bloom

  • 1Antiviral Gene Therapy Research Unit, School of Pathology, Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Future Microbiology
|November 9, 2013
PubMed
Summary
This summary is machine-generated.

Gene therapy offers a promising approach to silence Hepatitis B virus (HBV) gene expression, addressing limitations of current treatments. Research focuses on overcoming challenges like immune response and delivery for effective HBV gene therapy.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Experiment Videos

Last Updated: May 6, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Area of Science:

  • * Hepatology and Viral Immunology
  • * Gene Therapy and Molecular Medicine

Background:

  • * Chronic Hepatitis B virus (HBV) infection is a significant global health issue with limited curative therapies.
  • * Existing treatments often fail to prevent long-term complications associated with persistent viral infection.

Purpose of the Study:

  • * To review the potential of gene therapy, specifically RNA interference (RNAi), for treating chronic HBV infection.
  • * To discuss novel strategies addressing challenges in current gene therapy approaches for HBV.

Main Methods:

  • * Review of recent advancements in chemical modifications of anti-HBV small interfering RNAs (siRNAs).
  • * Exploration of diverse vector systems for efficient delivery of RNAi effectors.
  • * Analysis of strategies to mitigate immune stimulation and off-targeting effects.

Main Results:

  • * Chemical modifications and advanced delivery vectors show promise in enhancing the efficacy of RNAi-based HBV therapies.
  • * New approaches are being developed to overcome the limitations of immune stimulation and off-targeting.
  • * Gene therapy, particularly RNAi, presents a viable strategy for silencing HBV gene expression.

Conclusions:

  • * Gene therapy holds significant potential for developing effective treatments for chronic HBV infection.
  • * Continued research into optimized RNAi activators and delivery systems is crucial for clinical translation.
  • * Addressing safety concerns like immune response and off-targeting is key for successful HBV gene therapy.